Search

Introduction: Transthyretin cardiac amyloidosis (ATTR-CM) is an important comorbidity associated with aortic stenosis. Multiple studies have shown that the prevalence of ATTR-CM in severe AS is 15-20%. Concomitant AS and ATTR-CM confers worse outcomes than lone AS. Hypothesis: The purpose of this quality improvement project is to raise awareness of ATTR-CM in patients TAVR amongst the provider and patients. Methods: We retrospectively reviewed TAVR cases performed at our institution in 2019 (Total cases 87). We interrogated the presence of predefined high-risk features for ATTR-CM based on prior literature and guidelines. We subsequently contacted the identified subjects to discuss our suspicion of ATTR-CM and offered clinical referral to a cardiac amyloid specialist. Results: Of the total of 87 patients who underwent TAVR in 2019, 12 patients were deceased at time of chart review. We reviewed 75 patient medical records, of which 50 patients (66.7%) had high-risk features of ATTR-CM. Total of 19 patients (38%) agreed to being referred to a cardiac amyloid specialist. In addition, 7 more patients were found to be deceased on phone call (total 19 patients deceased), 18 patients could not be reached, and 6 patients declined referral. Conclusions: Comprehensive risk assessment approach in patients with severe AS may disclose otherwise unsuspected ATTR-CM and allow earlier diagnosis and treatment. These findings served as the basis for implementation of a prospective screening process for ATTR-CM utilizing pyrophosphate nuclear scanning in select patients referred for TAVR in our institution.